Key result
In patients undergoing mitral surgery, severe pulmonary hypertension was associated with 0.98% hospital mortality versus 0% for moderate pulmonary hypertension, with significant postoperative sPAP reductions.
Why the study?
Does mitral valve surgery improve pulmonary arterial systolic pressure and survival in patients with rheumatic mitral disease and pulmonary hypertension?
Observational (n=201)
No
Does mitral valve surgery improve pulmonary arterial systolic pressure and survival in patients with rheumatic mitral disease and pulmonary hypertension?
Mitral valve surgery in patients with rheumatic heart disease and severe pulmonary hypertension leads to significant reductions in pulmonary pressures and excellent long-term survival, suggesting severe PAH should not be an absolute contraindication.
Answers are grounded in this paper and cite their sources.
May support mitral surgery in severe PH; leaves open need for randomized survival confirmation.
Introduction: Rheumatic heart diseases are redoubtable complication of acute articular rheumatic. Without treatment, pulmonary hypertension and right heart failure may occur. This pulmonary hypertension was admitted as predictor of worse outcome after surgery. The aim of our study is to value the results after mitral surgery in patients with moderate and severe pulmonary hypertension. Methods: This is an observational descriptive retrospective study between January 2006 and December 2012; a total of 201 patients were operated for mitral or mitro-tricuspid disease with pulmonary arterial hypertension in “Djeghri Mokhtar” hospital. These patients are divided into two groups according to preoperative pulmonary hypertension (PAH) degree: (Group A: 102 patients in moderate PAH, 40 ≤ sPAP<60 mmHg; Group B: 99 patients in severe PAH, Spap ≥ 60 mmHg). In our study, sPAP was measured with doppler echocardiography. Preoperative, operative and postoperative data collection included age, sex, functional class, type of surgery and cardiopulmonary bypass. Pulmonary arterial systolic pressure, left atrial diameter, left ventricular end-diastolic diameter, and left ventricular ejection fraction were recorded and compared. Results: The follow up is in mean of 61.73 months (from 30 to 108 months). The functional class was improved in majority of patients. There is a significant decrease in mean sPAP during follow up:(48.72 ± 5.85 versus 29.12 ± 8.29 mmHg in group A;77.90 ± 15.62 versus 28.87 ± 10.61 mmHg in group B). Global hospital mortality is 0.49% (0% in group A, 0.98% in group B). Late mortality is 2.48%( 3.92% in group A; 1.01% in group B). Survival at 05 years is 96.5%. Conclusion: Pulmonary arterial systolic pressure decreased near normal value in most patients after surgery. Severe pulmonary hypertension must not be an absolute contraindication for mitral surgery, the outcome has been improved by developing cardiopulmonary bypass, myocardial protection and anesthetic technique.
No takes yet. Share an insight, caveat, or question.
Bendjaballah et al. (2017) conducted an observational in Mitral or mitro-tricuspid disease with pulmonary arterial hypertension (n=201). Severe pulmonary hypertension (sPAP ≥ 60 mmHg) vs. Moderate pulmonary hypertension (40 ≤ sPAP < 60 mmHg) was evaluated on Global hospital mortality. In patients undergoing mitral surgery, severe pulmonary hypertension was associated with 0.98% hospital mortality versus 0% for moderate pulmonary hypertension, with significant postoperative sPAP reductions.
Synapse has enriched 10 related papers. Consider them for comparative context: